Raynaud's Phenomenon Related with Atomoxetine Treatment in a Child with Autism and Attention-Deficit/Hyperactivity Disorder

Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review

“…For safety, there were four meta-analyses/pooled analyses [ 16 , 18 , 19 , 39 ], 33 RCTs and associated extension studies [ 28 – 34 , 36 , 38 , 40 , 41 , 43 – 46 , 48 , 50 , 52 , 55 , 56 , 60 – 63 , 66 – 68 , 70 – 73 , 76 , 84 ], 11 cohort studies [ 53 , 54 , 58 , 69 , 74 , 79 , 83 , 86 , 87 , 90 , 91 ], and 16 case reports or case series [ 47 , 49 , 51 , 57 , 59 , 64 , 65 , 75 , 77 , 78 , 80 – 82 , 85 , 88 , 89 ]. Most of the meta-analyses and RCTs were conducted in patients with ADHD and autism spectrum disorders or ODD, and more information was available on treatment with MPHs and ATX in these patients, with very few studies on AMPs or GXR (Table 1 ).…”

“…Adverse events reported in case reports of patients receiving MPHs included exacerbation of obsessive behavior [ 82 ], visual and/or auditory hallucinations [ 47 , 49 , 51 , 64 ], severe agitation, and hyperactivity and/or irritability in three patients with ODD after switching from risperidone to MPHs [ 85 ]. Adverse events reported in case reports of patients receiving ATX included Raynaud’s phenomenon [ 65 ] and onset of mania and auditory hallucinations when a patient titrated up to 40 mg/day [ 78 ]. Lethargy, bradycardia, and hypertension were reported in a patient with ADHD and Tourette’s disorder who ingested threefold his prescribed dose of GXR [ 57 ].…”